PLATIPUS is an adaptive platform trial aimed at improving the health of infants born preterm (before 37 weeks' gestation). PLATIPUS will compare how different treatments and care provided to pregnant women and people at risk of preterm birth and infants born preterm affect infant health.
The main questions PLATIPUS aims to answer are:
1. What effect/s do different treatments/care provided to pregnant women and people at risk of preterm birth have on the health of their infants? (Pregnancy domains)
2. What effect/s do different treatments/care given to infants born preterm have on their health ? (Neonatal domains).
This registration record relates to the PLATIPUS Core (or 'master') protocol which provides guidance for the overall running of the trial. Additional appendices will outline the aims, questions, treatments, and activities for each separate research question (domain). Each Domain-Specific Appendix will be registered separately on ClinicalTrials.gov and will link to this record.

开始日期2025-02-01

申办/合作机构

University of Melbourne

[+10]

TCTR20240626004

/ Not yet recruiting临床3期IIT

Enteral erythromycin versus intravenous metoclopramide for treatment of feeding intolerance in critically ill patients

开始日期2024-09-01

申办/合作机构-

NCT06574204

/ Not yet recruitingN/AIIT

The Mechanism and Clinical Observations of Pain and Pruritus Induced by Exposure to Allergic Contact Dermatitis Resulting From Macrolides

Clinical side effects of macrolides in addition to the common gastrointestinal reactions, recently it has been found that the incidence of local reactions after injection is relatively high, such as pain and itching and local inflammation. Severe skin reactions include erythema multiforme, acute systemic eruption impetigo, Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reactions with eosinophilia and systemic symptoms. The clinical study is a single-center, randomized, open, single-dose trial design. The clinical study plans to enroll 30 subjects to evaluate the incidence and severity of pain and pruritus after a single skin test in healthy subjects. A total of 30 subjects were randomly divided into 2 groups with 15 cases in each group. Erythromycin or azithromycin skin test will be performed on the left hand, and the same amount of normal saline will be injected into the right hand as the control. This clinical observation experiment helps improve the side effects and promotes upgrading macrolide antibiotics during clinical application.

开始日期2024-09-01

申办/合作机构

南通大学附属医院

100 项与红霉素相关的临床结果

登录后查看更多信息

100 项与红霉素相关的转化医学

登录后查看更多信息

100 项与红霉素相关的专利（医药）

登录后查看更多信息

24,967

项与红霉素相关的文献（医药）

2025-03-01·Chemosphere

An azide-based sampler for monitoring abiotic reduction of chlorinated solvent contaminants in groundwater

Article

作者: Bello, Dhimiter ; Yan, Weile ; Biswas, Kushal ; Fan, Lingfei

There is significant interest in monitoring abiotic decomposition of chlorinated solvents at contaminated sites due to large uncertainties regarding the rates of abiotic attenuation of trichloroethylene (TCE) and perchloroethylene (PCE) under field conditions. In this study, an innovative passive sampling tool was developed to quantify acetylene, a characteristic product of abiotic reduction of TCE or PCE, in groundwater. The sampling mechanism is based on the highly specific and facile click reaction between acetylene and an azide compound to form a biologically and chemically stable triazole product. In preliminary investigations using static solutions of acetylene, a strong linear relationship was observed between the quantity of azide formed and the concentration of aqueous acetylene. The product yield was stable within a solution pH range of 5-9 and in the presence of common groundwater salts or gaseous hydrocarbon molecules. Based on these results, a prototypical acetylene passive sampler was constructed, which featured a piece of PDMS membrane embedded with an azide compound and Cu(0) catalyst to form a reactive phase for acetylene capture. The sampler was evaluated in microcosm reactors containing TCE and an abiotic reductant (viz., sulfur-treated iron powder). Acetylene produced during abiotic dechlorination of TCE was effectively captured by the sampler, and the quantity of the product recovered from the sampler correlates with the amount of TCE converted. The specificity and sensitivity of the proposed acetylene sampler proffers a new diagnostic tool for monitoring abiotic degradation of chlorinated ethenes at complex contamination sites.

2025-03-01·Journal of Global Antimicrobial Resistance

Emergence of T4SS-type-ICE-carrying emm28 Streptococcus pyogenes causing invasive infection in Shanghai, China

Article

作者: Jiang, Yue ; Wu, Qiong ; Lv, PanPan ; Chen, Mingliang

OBJECTIVEInvasive group A streptococcal (iGAS) infections have been increasing in Europe, Australia, and the USA, but few data from China are available. This study intended to provide local data to highlight the characteristics of iGAS infections in China.METHODSA retrospective analysis was performed on clinical iGAS infection data from 2014 to 2023 in a tertiary hospital in Shanghai, China. Genomic analysis was conducted to characterize antimicrobial resistance, virulence, prophages, and integrative and conjugative elements (ICEs), as well as phylogenetic clusters.RESULTSFrom 2014 to 2023, a total of 21 iGAS cases were discovered, with soft tissue infections accounting for 61.9% (13/21) and 85.7% (18/21) of isolates resistant to erythromycin and clindamycin, respectively. Three iGAS isolates from 2023 underwent genome sequencing, which indicated that two isolates were emm12 and one was emm28. Phylogenetic analysis showed that the two emm12 isolates were assigned to clade II and closely related to Chinese scarlet fever-causing isolates. The emm28 isolate was assigned to subclades of SC1A and discovered to possess a novel ICE (designated as ICE-SHemm28; Tn916-like) that carried both the ermB gene and the type IV secretion system.CONCLUSIONSEmergence of an emm28 iGAS strain harboring a novel macrolide resistance-carrying type IV secretion system ICE was identified in invasive infections in Shanghai.

2025-02-01·Experimental Parasitology

Bioactive-based spray and spot-on formulations: Development, characterization and in vitro efficacy against fleas and ticks

Article

作者: Cid, Yara Peluso ; da Silva de Lima, Karen Kuhfuss ; Nascimento, Alice Ortega do ; Ferreira, Thais Paes ; Miranda, Fernando Rocha ; Avelar, Bárbara Rauta de ; Campos, Diefrey Ribeiro ; Jesus, Ingrid Lins Raquel de

The flea Ctenocephalides felis felis and the tick Rhipicephalus sanguineus are ectoparasites of great importance in veterinary medicine that can affect pets, also impacting the lives of owners due to the possible transmission of zoonoses. Due to the negative impact on animals, owners and the environment, synthetic chemicals are being replaced by natural alternatives. Eugenol and carvacrol stand out as bioactive substances with potential antiparasitic activity. The aim of the present study was to develop and characterize physicochemically spray and spot-on formulations containing bioactives alone and in combination and to evaluate their ectoparasiticidal activity through in vitro bioassays of the knockdown effect and residual efficacy against adult fleas and ticks. Regarding flea knockdown, spot-on formulations achieved maximum mortality in a shorter period than spray formulations, 2 h for carvacrol plus eugenol (SCE) and 4 h for carvacrol (SC) and eugenol (SE) alone, compared to 15, 30 and 45 min for the spot-on formulations of carvacrol (PC), both substances together (PCE) and eugenol alone (PE), respectively. For tick control, the formulations required longer exposure times than for fleas, so that 100% control took 6 h for PCE, followed by 12 h for SCE and PE, and 24 h for PC, SC and PE. Regarding residual efficacy against fleas, the spray and spot-on formulations remained active for approximately 90 and 45 days, respectively. In general, formulations containing associated bioactives had a faster knockdown effect than formulations with only one in their composition, indicating a synergistic effect of the two bioactive substances against fleas and ticks.

182

项与红霉素相关的新闻（医药）

2025-01-17

·医药速览

抗生素失效，耐药菌崛起背后的分子战场

我们知道，抗生素是一类由微生物或其他生物合成的次生代谢产物或其人工衍生物，在很低浓度时就能起作用。笔者上高中时生物老师就一直在强调这个问题：抗生素耐药性问题很严重！其主要原因是抗生素在养殖业和人为行为中的广泛使用，导致环境中抗生素污染严重，耐药菌才不断涌现。耐药性的分子机制是指微生物通过多种分子途径抵抗抗菌药物作用的能力，分为“内在性”耐药（利用自身基因抵抗抗生素）和“获得性”耐药（通过获取新的遗传物质获得生存能力）。这些机制包括抗生素失效、减少药物进入、改变靶点及活性抗药系统等。研究微生物耐药性的分子机制有助于开发新的治疗策略。今天就一起来学习一下耐药性的分子机制。 1. 降解或修饰抗生素：微生物通过产生酶来降解或化学修饰抗生素，使其失去活性。比如常见菌种大肠杆菌中β-内酰胺酶水解β-内酰胺类抗生素（如青霉素、头孢菌素），破坏其β-内酰胺环。常见的还有一种为氨基糖苷修饰酶通过磷酸化、乙酰化或腺苷化修饰氨基糖苷类抗生素（如链霉素），使其失去与靶点结合的能力。图1：抗生素失活机制 2. 改变抗生素靶点：通过突变或修饰抗生素的作用靶点，微生物使药物无法有效结合。例如核糖体蛋白或rRNA的改变会导致大环内酯类（如红霉素）、氨基糖苷类抗生素失效；喹诺酮类抗生素（如环丙沙星）靶向的DNA旋转酶（DNA gyrase）发生基因突变，降低药物结合能力；图2：靶点保护机制 3. 降低药物的内流或增加药物的外排：微生物通过调控药物摄入通道或利用外排泵减少药物浓度。例如革兰氏阴性菌外膜孔蛋白突变会减少β-内酰胺类、喹诺酮类药物的透过。药物外排泵则是通过主动运输系统将药物泵出细胞。常见的有MFS（主要促进大环内酯类和四环素类药物外排）。 4 代谢旁路的启用：通过改变代谢途径或激活替代通路，微生物绕过抗生素的作用。其中有叶酸代谢旁路：某些细菌通过外源性获取叶酸，绕过磺胺类药物对叶酸合成的抑制；多肽合成途径旁路：万古霉素耐药的肠球菌通过合成改良型的D-丙氨酰-D-乳酸（而非D-丙氨酰-D-丙氨酸），避免万古霉素与细胞壁前体结合。图3：代谢旁路启用机制 5. 形成生物膜：微生物在宿主组织或人工表面形成生物膜，从而降低抗生素渗透并增加耐药性。生物膜内细胞代谢较慢，对抗生素的敏感性下降，而且生物膜基质会限制药物的扩散。常见有铜绿假单胞菌（在肺部感染中形成生物膜）和表皮葡萄球菌（在医疗器械感染中形成生物膜）。 6. 基因水平的抗药性传播：微生物通过基因突变或水平基因转移获取抗药性基因。基因突变主要是自发突变使靶点结构改变或调节基因表达。水平基因转移则包括有①转化：吸收环境中的抗药性DNA片段；②转导：通过噬菌体将抗药性基因转移给其他细菌；③接合：通过质粒（如R质粒）传递抗药性基因。 7. 抗药基因的调控：通过调节基因表达，微生物可以快速应对抗生素的压力。主要包括调节外排泵基因和抗生素酶基因。图4：耐药性主要的分子机制总结在这些耐药性的分子机制中，药物的外排机制最为重要，通常与其他耐药机制协调发挥作用。微生物的抗药性是一个复杂且多因素的过程，涉及酶的生产、靶点改变、代谢调整、外排系统及生物膜形成等多种机制。这些机制可以单独作用，也可以联合作用使微生物产生极强的耐药性。所以，耐药性的治理和新技术的开发是当今人类面临的大问题，人人都将会受益。图5：一些抗生素的主要信息表示 Ref. 1.Darby E M, et al. Molecular mechanisms of antibiotic resistance revisited[J]. Nature Reviews Microbiology, 2023 2.Rather MA, et al. Microbial biofilm: formation, architecture, antibiotic resistance, and control strategies. Braz J Microbiol. 2021 Dec;3. Boneca IG. The Future of Microbial Drug Resistance. Microb Drug Resist. 2021 Jan;4. Christaki E, et al. Antimicrobial Resistance in Bacteria: Mechanisms, Evolution, and Persistence. J Mol Evol. 2020 Jan 推文用于传递知识，如因版权等有疑问，请于本文刊发30日内联系医药速览。原创内容未经授权，禁止转载至其他平台。有问题可发邮件至yong_wang@pku.edu.cn获取更多信息。 ©2021 医药速览保留所有权利往期链接 “小小疫苗”养成记 | 医药公司管线盘点人人学懂免疫学 | 人人学懂免疫学（语音版）综述文章解读 | 文献略读 | 医学科普 | 医药前沿笔记 PROTAC技术 | 抗体药物 | 抗体药物偶联-ADC 核酸疫苗 | CAR技术 | 化学生物学温馨提示医药速览公众号目前已经有近12个交流群（好学，有趣且奔波于医药圈人才聚集于此）。进群加作者微信（yiyaoxueshu666）或者扫描公众号二维码添加作者，备注“姓名/昵称-企业/高校-具体研究领域/专业”，此群仅为科研交流群，非诚勿扰。简单操作即可星标⭐️医药速览，第一时间收到我们的推送 ①点击标题下方“医药速览” ②至右上角“...” ③点击“设为星标

微生物疗法生物类似药

2025-01-06

·Pharmaceutical Technology

Danish biotech Orbis secures $94m to develop oral versions of biologics

The funds will support the development of Orbis’ pipeline of next-generation oral macrocycle drugs. Credit: sanjeri via Getty Images. Denmark-based biotech Orbis Medicines has raised €90m ($94m) in a Series A funding round to advance the development of its next-generation orally dosable macrocycle drugs, which the company calls ⁿCycles. The financing was led by New Enterprise Associates (NEA) with participation from new investors, including Eli Lilly, Cormorant, and the Export and Investment Fund of Denmark. The company – which launched in February 2024 with $28m (€26m) in seed funding from Novo Holdings and Forbion – is focused on creating oral alternatives to injectable biologics, particularly for chronic diseases, according to Orbis CEO Morten Graugaard. Orbis aims to address longstanding challenges in developing macrocycles – large ring-like compounds made from amino acids or other building blocks – into oral drugs. These compounds have strong therapeutic potential due to their ability to bind selectively to biological targets such as the immunosuppressant cyclosporine and the antibiotic erythromycin, but have historically faced issues with stability, absorption, and bioavailability. The biotech’s initial focus is on programmes against targets that are already validated by blockbuster biologic drugs to provide oral alternatives for patients who might prefer to take a pill rather than having treatments injected or by intravenous (IV) infusion. In September 2024, Orbis announced a research collaboration with Vivtex to leverage its gastrointestinal robotic interface system (GI-ORIS), a platform designed to assess gut permeability, which is crucial for determining the oral bioavailability of Orbis’ ⁿCycles portfolio. A month later, the company announced a significant expansion of its operations and capabilities by joining Symbion’s new biotech startup hub in Fuglebakken, Copenhagen. The macrocycle space is gaining some momentum across the pharmaceutical industry. MSD is in late-stage clinical development for macrocyclic peptide drug MK-0616 (enlicitide decanoate) targeting PCSK9 in patients with hypercholesterolemia. The candidate, which is currently being investigated in several Phase III studies, is forecast to generate $1.5bn by 2030 if approved, according to GlobalData. GlobalData is the parent company of Pharmaceutical Technology. MSD further displayed its interest in the space by entering a $220m deal with Unnatural Products (UNP), an AI-based biotech developing macrocyclic candidates. Competitors such as Circle Pharma have also made progress, raising $54m in a Series D round in July 2024 and signing a deal with Boehringer Ingelheim in October. “We have a clear strategy for rapid value creation that leverages the unique capabilities of our ⁿGen platform and are excited to advance this important new class of drugs for patients,” said Graugaard in the announcement accompanying the funding.

临床3期多肽偶联药物

2024-12-23

·药筛

布比卡因脂质体仿制不批准，久安肾上腺素注射液（预充式）上市申请 | 仿制药周报（12.16-12.22）

统计每周仿制药一致性评价申报、上市申请（12.16-12.22） 1、仿制药上市申请获批药品名称企业名称类型受理号氨溴特罗口服溶液海门普适医药有限公司3CYHS2302491布比卡因脂质体注射液浙江圣兆药物科技股份有限公司;杭州澳亚生物技术股份有限公司3CYHS2403649布比卡因脂质体注射液浙江圣兆药物科技股份有限公司;杭州澳亚生物技术股份有限公司3CYHS2403648复合磷酸氢钾注射液仁合益康汇泽药业河北有限公司;河北仁合益康药业有限公司3CYHS2400682黄体酮注射液北京布霖生物科技有限公司;华夏生生药业（北京）有限公司3CYHS2301078黄体酮注射液华夏生生药业（北京）有限公司3CYHS2301003甲硝唑凝胶江苏晨牌邦德药业有限公司4CYHS2301950硝普钠注射液南京泽恒医药技术开发有限公司;天津金耀药业有限公司3CYHS2301878盐酸环喷托酯滴眼液沈阳兴齐眼药股份有限公司4CYHS2303317盐酸肾上腺素注射液马鞍山丰原制药有限公司3CYHS2400756乙酰半胱氨酸注射液合肥国药诺和药业有限公司;国药集团国瑞药业有限公司3CYHS2400493乙酰半胱氨酸注射液福安药业集团庆余堂制药有限公司3CYHS2301671 注：灰色字体部分受理号结论为不批准。 2、一致性评补充申请获批药品名称企业名称类型醋酸泼尼松片安徽金太阳生化药业有限公司CYHB2450402甲硝唑片湖北省宏源药业科技股份有限公司;湖北同德堂药业有限公司CYHB2350652聚普瑞锌颗粒吉林省博大伟业制药有限公司CYHB2350908硫酸阿米卡星注射液浙江诚意药业股份有限公司CYHB2350563尼可地尔片天方药业有限公司CYHB2450242维生素B6片山西亨瑞达制药有限公司CYHB2150625盐酸丁螺环酮片北大医药股份有限公司CYHB2350812盐酸丁螺环酮片北大医药股份有限公司CYHB2350813盐酸二甲双胍肠溶胶囊北京圣永制药有限公司CYHB2350790盐酸二甲双胍肠溶胶囊北京圣永制药有限公司CYHB2350789盐酸伐昔洛韦片湖北广济药业股份有限公司CYHB2450037注射用哌拉西林钠他唑巴坦钠海口奇力制药股份有限公司CYHB2350895注射用哌拉西林钠他唑巴坦钠海口奇力制药股份有限公司CYHB2350897注射用哌拉西林钠他唑巴坦钠海口奇力制药股份有限公司CYHB2350896注射用头孢哌酮钠舒巴坦钠(2:1)广东金城金素制药有限公司CYHB2350849注射用头孢哌酮钠舒巴坦钠(2:1)广东金城金素制药有限公司CYHB2350848注射用头孢他啶苏州二叶制药有限公司CYHB2350861注射用头孢他啶苏州二叶制药有限公司CYHB2350860注射用头孢他啶苏州二叶制药有限公司CYHB2350859注射用头孢西丁钠浙江惠迪森药业有限公司CYHB2350845注射用头孢西丁钠浙江惠迪森药业有限公司CYHB2350846 注：灰色字体部分受理号结论为不批准。 3、新增仿制药上市申请药品名称企业名称类型受理号阿法骨化醇软胶囊南京海鲸药业股份有限公司4CYHS2404441阿法骨化醇软胶囊南京海鲸药业股份有限公司4CYHS2404443他达拉非片珠海联邦制药股份有限公司中山分公司4CYHS2404459甲磺酸沙非胺片南京正大天晴制药有限公司4CYHS2404454枸橼酸西地那非片广东培杰药物研究有限公司;江苏永安制药有限公司4CYHS2404446枸橼酸氢钾钠颗粒成都恒瑞制药有限公司4CYHS2404449盐酸伐昔洛韦片浙江车头制药股份有限公司;杭州领业医药科技有限公司4CYHS2404440他达拉非片珠海联邦制药股份有限公司中山分公司4CYHS2404458碘[131I]化钠口服溶液广东君奇医药科技有限公司3CYHS2404438玻璃酸钠滴眼液江苏福邦药业有限公司4CYHS2404460阿法骨化醇软胶囊南京海鲸药业股份有限公司4CYHS2404444维生素B6注射液江西远超医药科技有限公司;朗天药业（湖北）有限公司3CYHS2404453他达拉非片珠海联邦制药股份有限公司中山分公司4CYHS2404457注射用硫酸艾沙康唑湖南科伦制药有限公司4CYHS2404461甲磺酸沙非胺片南京正大天晴制药有限公司4CYHS2404455比索洛尔氨氯地平片江苏德源药业股份有限公司4CYHS2404456枸橼酸西地那非片广东培杰药物研究有限公司;江苏永安制药有限公司4CYHS2404448甲磺酸沙非胺片石家庄四药有限公司4CYHS2404435恩他卡朋双多巴片（Ⅱ）浙江京新药业股份有限公司4CYHS2404442重酒石酸去甲肾上腺素注射液山西普恒制药有限公司3CYHS2404450枸橼酸西地那非片广东培杰药物研究有限公司;江苏永安制药有限公司4CYHS2404447双氯芬酸钠肠溶片四川天德制药有限公司4CYHS2404451复合磷酸氢钾注射液内蒙古白医制药股份有限公司3CYHS2404445依折麦布阿托伐他汀钙片（II）重庆圣华曦药业股份有限公司4CYHS2404452丁溴东莨菪碱注射液广东博卓医药科技有限公司;烟台鲁银药业有限公司4CYHS2404439盐酸溴己新口服溶液河北汇德旭盛医药科技有限公司;石家庄科仁医药科技有限公司3CYHS2404428注射用乳糖酸红霉素广东态森德制药有限公司;广东星昊药业有限公司3CYHS2404422盐酸溴己新口服溶液河北汇德旭盛医药科技有限公司;石家庄科仁医药科技有限公司3CYHS2404429双氯芬酸依泊胺贴杭州端本医药科技有限公司;南京海纳制药有限公司3CYHS2404427尼莫地平口服溶液江苏联环药业股份有限公司3CYHS2404430注射用磷酸特地唑胺吉林津升制药有限公司4CYHS2404420美阿沙坦钾片合肥立方制药股份有限公司4CYHS2404425甲磺酸沙非胺片石家庄四药有限公司4CYHS2404436美阿沙坦钾片合肥立方制药股份有限公司4CYHS2404426盐酸氮卓斯汀滴眼液江西马应龙美康药业有限公司;浙江尖峰药业有限公司4CYHS2404424注射用氟氧头孢钠四川制药制剂有限公司;浙江惠迪森药业有限公司4CYHS2404423盐酸尼卡地平注射液江西东抚制药有限公司4CYHS2404434甲磺酸沙非胺片四川科伦药业股份有限公司4CYHS2404431甲磺酸沙非胺片四川科伦药业股份有限公司4CYHS2404432尼莫地平口服溶液江苏联环药业股份有限公司3CYHS2404433盐酸赛庚啶口服溶液苏州华健瑞达医药技术有限公司;浙江京新药业股份有限公司3CYHS2404421苯磺贝他斯汀口崩片漯河市汇创医药有限公司;裕松源药业有限公司3CYHS2404404非奈利酮片天地恒一制药股份有限公司4CYHS2404406重酒石酸去甲肾上腺素注射液浙江尚科生物医药有限公司3CYHS2404416富马酸伏诺拉生片重庆世森医药科技有限公司;烟台鲁银药业有限公司4CYHS2404409比索洛尔氨氯地平片浙江百代医药科技有限公司;浙江赛默制药有限公司4CYHS2404419硫酸镁注射液江苏润恒制药有限公司3CYHS2404413卡泊三醇搽剂福元药业有限公司4CYHS2404415钆特醇注射液河北仁合益康药业有限公司4CYHS2404414环索奈德吸入气雾剂上海上药信谊药厂有限公司3CYHS2404405头孢克肟颗粒广东华南药业集团有限公司;金鸿药业股份有限公司3CYHS2404410倍他米松磷酸钠注射液河南利华制药有限公司;河南润弘制药股份有限公司3CYHS2404411吸入用盐酸丙卡特罗溶液合肥国药诺和药业有限公司;江苏大红鹰恒顺药业有限公司3CYHS2404418硫酸镁注射液江苏润恒制药有限公司3CYHS2404412富马酸伏诺拉生片重庆世森医药科技有限公司;烟台鲁银药业有限公司4CYHS2404408布美他尼注射液云南华派医药科技有限公司;楚雄和创药业有限责任公司3CYHS2404407吸入用盐酸丙卡特罗溶液合肥国药诺和药业有限公司;江苏大红鹰恒顺药业有限公司3CYHS2404417盐酸布比卡因注射液湖北津药药业股份有限公司3CYHS2404387阿昔莫司胶囊河北锐健医药科技有限公司;淄博万杰制药有限公司4CYHS2404391聚乙二醇4000散（儿童型）郑州泰丰制药有限公司3CYHS2404390熊去氧胆酸片中山百灵生物技术股份有限公司;安士制药（中山）有限公司3CYHS2404398小儿法罗培南钠颗粒广东九明制药有限公司4CYHS2404389阿贝西利片齐鲁制药有限公司4CYHS2404403盐酸奥洛他定滴眼液武汉新瑞医药科技有限公司;武汉五景药业有限公司4CYHS2404399盐酸尼卡地平注射液浙江花园药业有限公司4CYHS2404394培哚普利氨氯地平片（III）浙江华海药业股份有限公司4CYHS2404395夫西地酸乳膏西藏奥斯必秀医药有限公司;浙江康恩贝制药股份有限公司4CYHS2404386阿贝西利片齐鲁制药有限公司4CYHS2404402苯磺酸氨氯地平口服溶液四川奥邦古得药业有限公司;南京海纳制药有限公司3CYHS2404396盐酸伐地那非口崩片哈尔滨三联药业股份有限公司3CYHS2404392异氟烷福建海西联合药业有限公司4CYHS2404388盐酸丙卡特罗颗粒四川大冢制药有限公司3CYHS2404400格拉司琼透皮贴片杭州朱养心药业有限公司4CYHS2404393阿贝西利片齐鲁制药有限公司4CYHS2404401硫酸羟氯喹片珠海润都制药股份有限公司4CYHS2404397氢溴酸替格列汀片常州千红生化制药股份有限公司4CYHS2404378达格列净二甲双胍缓释片（Ⅰ）南通联亚药业股份有限公司4CYHS2404362替米沙坦氨氯地平片江苏百佑药业有限公司;山东丰金生物医药有限公司4CYHS2404374托吡酯片山东新时代药业有限公司4CYHS2404365阿托伐他汀钙片浙江江北药业有限公司4CYHS2404379吸入用盐酸丙卡特罗溶液石家庄四药有限公司3CYHS2404384夫西地酸乳膏广东科泓药业有限公司4CYHS2404370醋酸特利加压素注射液武汉华龙生物制药有限公司3CYHS2404363恩格列净二甲双胍缓释片山东力诺制药有限公司;重庆博腾药业有限公司3CYHS2404372肾上腺素注射液（预充式）武汉久安药物研究院有限公司;武汉久安药业有限公司3CYHS2404369硫代硫酸钠注射液赤峰源生药业有限公司3CYHS2404371氧氟沙星滴耳液江苏宝东医药科技有限公司;知和（山东）大药厂有限公司4CYHS2404382马来酸曲美布汀片浙江诺得药业有限公司3CYHS2404381氯法齐明软胶囊Dong-A ST Co., Ltd.5.2JYHS2400065复方电解质醋酸钠注射液浙江高跖医药科技股份有限公司;浙江赛默制药有限公司3CYHS2404375氨酚羟考酮片北京华素制药股份有限公司3CYHS2404364托吡酯片山东新时代药业有限公司4CYHS2404366妥布霉素滴眼液江苏宝东医药科技有限公司;知和（山东）大药厂有限公4CYHS2404383盐酸头孢卡品酯颗粒苏州盛达药业有限公司;苏州第三制药厂有限责任公司4CYHS2404377阿托伐他汀钙片浙江江北药业有限公司4CYHS2404380阿仑膦酸钠口服溶液湖北欣泽霏药业有限公司3CYHS2404385恩格列净二甲双胍缓释片山东力诺制药有限公司;重庆博腾药业有限公司3CYHS2404373盐酸溴己新口服溶液湖北民康药业集团有限公司;南京海纳制药有限公司3CYHS2404367依折麦布阿托伐他汀钙片（Ⅱ）浙江昂利康制药股份有限公司4CYHS2404376盐酸溴己新口服溶液湖北民康药业集团有限公司;南京海纳制药有限公司3CYHS2404368 4、新增一致性评价补充申报药品名称企业名称受理号盐酸吡格列酮分散片双鹤天安药业（贵州）股份有限公司CYHB2450619地高辛片上海上药信谊药厂有限公司CYHB2450620甲硝唑片贵州百灵企业集团制药股份有限公司CYHB2450618头孢克肟胶囊海南日中天制药有限公司CYHB2450613地塞米松磷酸钠注射液广州白云山天心制药股份有限公司CYHB2450616法莫替丁注射液国药集团容生制药有限公司CYHB2450615阿司匹林肠溶片广东彼迪药业有限公司CYHB2450617头孢克肟胶囊海南日中天制药有限公司CYHB2450614 数据来源：摩熵医药用摩熵药筛小程序，随时随地查周报

一致性评价上市批准

100 项与红霉素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00140	红霉素	J01FA01 D10AF02 S01AA17	DB00199

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
细菌感染	中国	大连天宇制药有限公司	1977-01-01
软下疳	日本	Viatris Healthcare GK	1955-10-13
白喉	日本	Viatris Healthcare GK	1955-10-13
脓胸	日本	Viatris Healthcare GK	1955-10-13
子宫内感染	日本	Viatris Healthcare GK	1955-10-13
肺脓肿	日本	Viatris Healthcare GK	1955-10-13
淋巴结炎	日本	Viatris Healthcare GK	1955-10-13
乳腺炎	日本	Viatris Healthcare GK	1955-10-13
骨髓炎	日本	Viatris Healthcare GK	1955-10-13
中耳炎	日本	Viatris Healthcare GK	1955-10-13
冠周炎	日本	Viatris Healthcare GK	1955-10-13
肺炎	日本	Viatris Healthcare GK	1955-10-13
肾盂肾炎	日本	Viatris Healthcare GK	1955-10-13
猩红热	日本	Viatris Healthcare GK	1955-10-13
梅毒	日本	Viatris Healthcare GK	1955-10-13
破伤风	日本	Viatris Healthcare GK	1955-10-13
扁桃体炎	日本	Viatris Healthcare GK	1955-10-13
尿道炎	日本	Viatris Healthcare GK	1955-10-13
百日咳	日本	Viatris Healthcare GK	1955-10-13

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04665089 (Pubmed \| J Crit Care)	N/A	脓毒症 TNF/IL-10 ratio \| Procalcitonin (PCT) \| CRP	-	Erythromycin	(窪鬱夢顧繭繭齋糧獵願) = 製範鏇鹹選艱壓衊壓鹽願鏇壓鏇構構簾鑰網鬱 (艱壓積積窪網蓋鑰築襯 )	不佳	2024-06-01
				Placebo	(窪鬱夢顧繭繭齋糧獵願) = 窪壓艱糧範選遞廠鑰醖願鏇壓鏇構構簾鑰網鬱 (艱壓積積窪網蓋鑰築襯 )
ADA2023	N/A	2型糖尿病	-	Moderate-intensity statin with ezetimibe combination therapy	(簾糧鬱襯艱選襯選鏇網): HR = 0.7 (95% CI, 0.52 ~ 0.93), P-Value = 0.014 更多	积极	2023-06-20
				High-intensity statin monotherapy
UEGW2021	N/A	消化道出血	71	Erythromycin	願繭觸膚簾獵願鹹夢淵(齋壓糧鹹鑰鑰鬱醖簾膚) = 夢蓋淵製築繭艱鹹鏇構窪糧襯齋簾憲積觸艱鏇 (鬱膚窪觸淵襯憲鑰獵窪 )	积极	2021-10-02
				Azithromycin 250mg	願繭觸膚簾獵願鹹夢淵(齋壓糧鹹鑰鑰鬱醖簾膚) = 壓淵鏇衊糧醖廠鏇選簾窪糧襯齋簾憲積觸艱鏇 (鬱膚窪觸淵襯憲鑰獵窪 )
NCT03480243 (CTgov)	临床1期	-	28	Padsevonil (Period 1) (PK-PPS) (Padsevonil (Period 1) (PK-PPS))	製糧繭繭積簾選鹽淵鑰(壓夢蓋鹽膚夢憲壓獵壓) = 壓憲製鹹鬱鬱齋製簾襯襯鹽製壓糧憲廠積獵壓 (餘鹹淵餘夢餘鏇繭願願, 淵夢壓簾艱獵夢艱製窪 ~ 衊觸醖獵觸壓範鏇糧願) 更多	-	2021-07-12
				Padsevonil (Period 2) (PK-PPS) (Padsevonil (Period 2) (PK-PPS))	製糧繭繭積簾選鹽淵鑰(壓夢蓋鹽膚夢憲壓獵壓) = 齋艱願鹽鹽鹽糧餘壓夢襯鹽製壓糧憲廠積獵壓 (餘鹹淵餘夢餘鏇繭願願, 艱顧餘鹽廠積獵鹽築鏇 ~ 繭範鏇鬱願積願築鹹鹹) 更多
ASCO2018	N/A	晚期非小细胞肺癌	7,298	Statin preparations	-	积极	2018-06-01
				Metformin preparations	(觸願糧製獵襯觸鹹壓鑰) = 膚衊構憲蓋簾蓋構鏇夢鬱鬱壓簾糧淵積膚遞網 (餘鬱顧襯蓋蓋遞壓積觸 )
NCT01890967 (CTgov)	临床2期	原发性高胆固醇血症	527	Placebo+Ezetimibe+Statin (Placebo Q4W)	製衊齋襯淵鑰獵範觸觸(艱齋獵淵鏇壓鹹醖窪膚) = 淵獵膚膚簾積選廠艱範壓膚淵築夢製齋遞鬱糧 (鑰膚壓鹹艱餘鏇鏇鹽艱, 蓋廠鹽築範醖鹽繭鏇餘 ~ 艱廠鹽膚艱壓鏇淵願膚) 更多	-	2017-06-21
				LY3015014+Ezetimibe+Statin (20 mg LY3015014 Q4W)	製衊齋襯淵鑰獵範觸觸(艱齋獵淵鏇壓鹹醖窪膚) = 獵鑰憲積顧願夢艱獵壓壓膚淵築夢製齋遞鬱糧 (鑰膚壓鹹艱餘鏇鏇鹽艱, 鹹鏇膚齋襯鹹積壓鏇鏇 ~ 築網鏇衊選糧艱遞醖鏇) 更多
NCT02005029 (CTgov)	N/A	帕金森病	18	Erythromycin (Erythromycin)	(壓選繭觸願衊繭襯願選) = 觸蓋膚膚窪繭襯積衊觸淵網網顧繭艱蓋窪蓋鹹 (憲選鏇糧顧窪鬱簾鬱範, 鏇鹽醖範鹹築選築艱衊 ~ 膚襯顧鹹構鹹觸願築獵) 更多	-	2017-02-03
				placebo (Placebo)	(壓選繭觸願衊繭襯願選) = 獵衊獵鏇廠齋艱鏇蓋鑰淵網網顧繭艱蓋窪蓋鹹 (憲選鏇糧顧窪鬱簾鬱範, 壓願製顧廠觸膚觸憲齋 ~ 餘齋獵憲鹹窪鹽衊餘齋) 更多
pilot study using erythromycin (WPC2016)	N/A	帕金森病	-	Erythromycin	構壓醖觸願蓋憲衊願齋(窪餘顧築憲願襯鹹衊顧) = A corresponding 15% increase in LD AUC 0-4hour was not statistically significant, however, likely due to the small sample size 繭遞簾鹽鹽窪鑰蓋願築 (衊鹽餘築廠廠築鑰艱構 )	积极	2016-09-01
NCT02481219 (CTgov)	N/A	结直肠癌	122	SUPREP oral sulfate solution+PEG+Metoclopramide+Bisacodyl+Senna tablets+Erythromycin (Bowel Preparation Regimen -Control)	選獵構齋簾醖鹹餘齋鏇(衊襯壓餘鹹遞憲醖艱襯) = 構範夢鹹遞網鑰鬱觸艱獵夢夢憲壓壓鹽鏇繭夢 (鑰構襯膚積繭簾顧衊製, 窪窪淵鬱選艱顧膚憲積 ~ 壓鹹觸鑰醖網選齋醖膚) 更多	-	2016-07-11
				SUPREP oral sulfate solution+PEG+Metoclopramide+Bisacodyl+Senna tablets+Erythromycin (Bowel Preparation Regimen-Test)	選獵構齋簾醖鹹餘齋鏇(衊襯壓餘鹹遞憲醖艱襯) = 壓窪鏇願糧遞醖鏇選獵獵夢夢憲壓壓鹽鏇繭夢 (鑰構襯膚積繭簾顧衊製, 鬱衊齋餘鏇構鏇糧壓膚 ~ 夢蓋範鬱艱獵築築網衊) 更多
Pubmed \| J Pediatr Gastroenterol Nutr	N/A	-	-	Erythromycin	顧鹽衊壓遞齋夢鹹蓋壓(壓壓夢觸範網顧窪鏇網) = 繭餘積獵淵鏇鹽蓋築膚鬱廠積簾構獵網醖膚鏇 (獵鏇鏇築膚構壓壓鏇艱 ) 更多	-	2015-09-01
				Metoclopramide	(鑰壓築襯選鏇築遞築夢) = 築窪鑰齋觸網獵憲壓鹹艱蓋構鑰繭廠衊獵網網 (鹹鏇糧膚網齋夢廠簾製 ) 更多